bioAffinity Technologies
BIAF
3 hedge funds and large institutions have $134K invested in bioAffinity Technologies in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0.21% more ownership
Funds ownership: 0.79% → 1% (+0.21%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
25% less funds holding
Funds holding: 4 → 3 (-1)
30% less capital invested
Capital invested by funds: $192K → $134K (-$58.5K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Financial Engines Advisors
Santa Clara,
California
|
+$164K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$60K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$44.4K |
| 3 |
Jane Street
New York
|
-$32K |
BIAF Hedge Fund Activity: Q4 2022 in Review
3 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q4 2022, worth a combined $134K — down 30% from $192K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIAF and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Financial Engines Advisors, opening a new position worth an estimated $164K. The largest seller was Citadel Advisors, exiting entirely with an estimated $60K sold.
- 3 institutional investors held bioAffinity Technologies (BIAF) as of Q4 2022, down from 4 in Q3 2022.
- Funds reported $134K of bioAffinity Technologies stock for Q4 2022, down 30% quarter-over-quarter.
- 1 fund opened new bioAffinity Technologies positions in Q4 2022 and 2 closed out, a net change of -1 holder.
- The largest bioAffinity Technologies buyer in Q4 2022 was Financial Engines Advisors, an estimated $164K added.
- The largest bioAffinity Technologies seller in Q4 2022 was Citadel Advisors, an estimated $60K sold.
Based on aggregated 13F filings for Q4 2022.